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database of year 2001. RESULTS: The economic evaluation indi-
cated the costing of chemotherapy drug acquisition per patient
for GC is NTD 128,872 (USD$3816) (1USD = $33.77NTD) and
NTD 151,293 (USD$4480), NTD 251,126 (USD$7436), NTD
143,377 (USD$4246) for PC, PCA and DC, respectively. The
average total cost per patient for GC is NTD 162,984
(USD$4826). This was lower than those treated with PC, PCA
and DC with average savings of NTD 33,389 (USD$989), NTD
116,962 (USD$3463) and NTD 20,611 (USD$610) per patient,
respectively. These results proved robust in light of a univariate
sensitivity analysis. CONCLUSIONS: GC was associated with
lower total treatment costs than PC, PCA and DC from the per-
spective of the national health reimbursement of Taiwan. Given
similar efﬁcacy ﬁndings in these studies, GC is offering cost-
savings potential in the treatment of advanced NSCLC is sup-
ported. The limitations of this research include the complex of
the disease; the conventional chemotherapy regimens as well as
the cost of approaches for adverse events management are dif-
ferent by each health care provider.
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OBJECTIVES: The efﬁciency of a radical prostatectomy (RP)
and a permanent seed implantation (PSI) was compared as ther-
apeutic alternatives in the treatment of stage T1-T2 prostate
cancer in Germany. METHODS: The comparison between PSI
and RP was made by a cost-effectiveness-analysis assisted by the
software DATA Professional. Costs, efﬁcacy and tolerability of
both alternatives were the evaluation parameters. Data for prob-
abilities of success and rates of adverse effects (AE) were taken
from international studies. Success of therapy was deﬁned as PSA
(prostate-speciﬁc antigen)-progression free survival within 7
years. Therapy failure was deﬁned as PSA levels >0.2ng/ml in
two successive readings for RP cases and three consecutive rising
PSA levels for PSI patients. Applying the perspective of the statu-
tory health insurance (SHI) PSI is more cost-effective compared
with RP. All direct (medical) costs of therapy of prostate cancer,
of therapy failure and of treatment of AE, reimbursed by SHI in
Germany, were considered. In accordance with the Hannover
consensus guidelines, costs were discounted at 5% pa.
RESULTS: Total costs amounted to 7691€ for a PSI and 8715€
for a RP. Effectiveness-adjusted costs at similar effectiveness rates
(0.76 PSI, 0.76 RP) amounted to 10,120€ for PSI and 11,468€
for RP. PSI therefore dominates the RP alternative. Two sensi-
tivity-analyses were conducted by varying probabilities of
success for each alternative. PSI dominates RP as long as prob-
ability of success of PSI is not lower than 0.68 or for RP not
higher than 0.85. CONCLUSIONS: Considering the perspective
of SHI, the therapy of stage T1-T2 prostate cancer with 
permanent seed implantation is more cost-effective than radical
prostatectomy.
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